Local and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAH.
OBJECTIVE:The molecular determinants of chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (iPAH) remain poorly understood. The receptor for advanced glycation endproducts (RAGE) and its ligands: HMGB1 and S100A9 are involved in inflammatory disorder...
Main Authors: | Bernhard Moser, Anna Megerle, Christine Bekos, Stefan Janik, Tamás Szerafin, Peter Birner, Ana-Iris Schiefer, Michael Mildner, Irene Lang, Nika Skoro-Sajer, Roela Sadushi-Kolici, Shahrokh Taghavi, Walter Klepetko, Hendrik Jan Ankersmit |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4154707?pdf=render |
Similar Items
-
Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology.
by: Bernhard Moser, et al.
Published: (2014-01-01) -
Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
by: Raymond L. Benza, et al.
Published: (2020-03-01) -
Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study
by: Suqiao Yang, et al.
Published: (2021-09-01) -
Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences
by: Asger Andersen, et al.
Published: (2017-01-01) -
The intracellular distribution and target of IpaH4.5 and IpaH7.8
by: Chun-Yi Lee, et al.
Published: (2009)